Navigation Links
Avidity Biosciences Announces Publication on Targeting Therapeutic Oligonucleotides by Arthur A. Levin in the New England Journal of Medicine
Date:1/5/2017

LA JOLLA, Calif., Jan. 4, 2017 /PRNewswire/ -- Avidity Biosciences LLC, a biotechnology company advancing Antibody-siRNA Conjugates (ASCs) as a new class of precision medicines, today announced a publication entitled, "Targeting Therapeutic Oligonucleotides," in the January 5, 2017 issue of the New England Journal of Medicine.1 The publication, authored by Arthur A. Levin, Ph.D., executive vice president of research and development, appears in the Clinical Implications of Basic Research section.

In the publication, Dr. Levin summarizes the advantages of targeted strategies for the delivery of therapeutic oligonucleotides. 

"Recent work indicates that the usefulness of therapeutic oligonucleotides can be increased by conjugating oligonucleotides with targeting moieties so that they home to specific cell types," said Dr. Levin. "Targeted delivery was determined to result in a median effective dose that was one thirtieth of that associated with non-targeted delivery, which clearly underscored the potential advantage of the approach."

Levin continues, "There remains a need to target non-hepatic cells specifically and efficiently: a means to achieve this goal could lie in the exploitation of the natural heterogeneity of cell surface receptors."

Dr. Levin has an unparalleled track record and reputation in the field of nucleic acid-based therapeutics. Prior to his role at Avidity Biosciences, he held senior drug development roles at miRagen Therapeutics, Ionis Pharmaceuticals and Santaris Pharma. He has played key roles in the development of numerous oligonucleotides, including the first approved antisense NDAs and the first microRNA-targeted therapeutic in clinical trials. He has a combined three decades of experience in all aspects of drug development from discovery through drug registration, both in large pharma and biotech companies. Dr. Levin has published over 60 scientific articles and has several of the most cited reviews in the field. He serves as a director of the Oligonucleotide Therapeutics Society and holds several additional scientific organization affiliations and honors. He received a doctorate in toxicology from the University of Rochester and a bachelor's degree in biology from Muhlenberg College.

About Avidity Biosciences

Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASCs) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics. Avidity is collaborating with partners to discover and develop best-in-class drug candidates against important undrugged therapeutic targets. The company has entered research collaborations with leading biopharma companies and is actively seeking additional partnerships. Avidity has raised $25 million in venture financing from a top-tier group of sophisticated healthcare investors.  More information about Avidity Biosciences can be found on the company's website at www.aviditybiosciences.com.

1  Levin, A, Targeting therapeutic oligonucleotides. N Engl J Med 2016;376: 86-88.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avidity-biosciences-announces-publication-on-targeting-therapeutic-oligonucleotides-by-arthur-a-levin-in-the-new-england-journal-of-medicine-300385825.html


'/>"/>
SOURCE Avidity Biosciences
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Biotech Stocks on Investors Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx
2. Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down
3. DuPont Industrial Biosciences to Begin New Research Aimed to Enable Global Access for Protein Medications
4. Roche announces termination of 2013 Development, Commercialization and License Agreement with Pacific Biosciences
5. ACEA Biosciences Presents Efficacy and Safety Data From AC0010 Phase I/II Clinical Trial for Treatment of Advanced Non-Small Cell Lung Cancer at the WCLC 2016 Conference
6. ACEA Biosciences Announces Data Presentation at WCLC 2016 Conference: New AC0010 Data to Be Presented
7. Vigene Biosciences Acquires the cGMP Manufacturing Facility and Assets of Omnia Biosciences
8. ACEA Biosciences Appoints Li Xu, M.D. as Chief Medical Officer
9. DuPont Industrial Biosciences and MIAVIT Announce Supply Agreement for Biogas Enzymes
10. Agro BioSciences Expands Probiotic Strain Portfolio
11. ARMO BioSciences Immunotherapy AM0010 Receives Orphan Drug and Fast Track Designations from the U.S. FDA for the Treatment of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2018)... ... September 06, 2018 , ... Cognition® Corporation ... the agenda for its upcoming user conference. , This year NAVIGATE2018 ... challenges, opportunities, and approaches to regulatory compliance and quality management. , “We’ve got ...
(Date:8/31/2018)... (PRWEB) , ... August 29, 2018 , ... ... Professorships at both the University of Southampton and the Institute of Industrial Science, ... intelligence at sea can dramatically accelerate the exploration and study of hard to ...
(Date:8/29/2018)... ... 28, 2018 , ... Inc. Magazine has announced that ... 1138th place on the 27th annual Inc. 5000, the most prestigious ranking of ... successful companies within the American economy’s most dynamic segment – independent small businesses. ...
(Date:8/26/2018)... ... 23, 2018 , ... LabRoots , the leading provider ... world, will host the 4th Annual Microbiology and Immunology Virtual Event September 12-13. ... various research areas including medicine, agriculture, and space. , During the free, ...
Breaking Biology Technology:
(Date:9/7/2018)... ... September 05, 2018 , ... Following up on the ... last year, IPS-Integrated Project Services, LLC and G-CON Manufacturing have successfully designed and ... iCON solution provides a pre-fabricated modular cleanroom infrastructure for the drug manufacturers’ requirements ...
(Date:9/1/2018)... ... ... is hard at work on his second ocean crossing. After becoming the first human to ... to San Francisco, churning his limbs eight hours a day in the cold Pacific for ... its kind, The Swim is far more than just an extreme sport. Besides the gruelling ...
(Date:8/31/2018)... Wisc. (PRWEB) , ... August 30, 2018 , ... ... measure inhibitor residence times as a component of drug discovery programs. Longer-target engagement ... these residence times are low throughput, require expensive instrumentation, or require the alteration ...
Breaking Biology News(10 mins):